IT was a fair article. Showed both sides. I wish it would have said more about barda and AMGENs" problem with ramping EBOLA animal cells ZMAPP. The antibodies are not growing well with animal cells. Plant antibodies grow much faster and easier. Will this impact the BARD decision? It has to some degree. I think they will produce animal and cell ZMAPP. his put a greater emphasis on plants and Caliber......... The piece just said it is a hurdle they have to over come.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Robert was right again.
Many have animal based cures.... Not ebola but general virus drugs //////// NONE TESTED..... ITS a good way to get rid of the old virus drugs that wont work.... THE press has stated no drugs have been tested on humans up until recently. ITS funny how these animal based hard and slow to make drugs have been popping up occasionally..... NO human testing and many haven't ben tested on animals at all. BOY and Melissa thinks IBIO pumped up and hyped a drug and took advantage of ebola.... SHE thinkls IBIO is the only one to co0me up with a drug or solution. She is delusional.
ITS THE BIGGEST and best for plantibodies. ACTUALY its the only move ..... Its a no brainer..... So you have no brain posting that #$%$..... Who else???? Answer r go home mad/
its still on Yahoo headlines. She is a Yahoo contributor. I wish Yahoo had a flag so we could all flag her. They do allow comments. I would go tell her to go to @#$%^&*(). Do it under the article on Yahoo.
I claim you a fool...... that has more merit............... read ZMAPP problems if you don't believe Robert. IBIO is just the way. !!!!!!!!!!!!!!!!!!!!
no claim made. Just hot air and investigations. They will find a great company that is ready to rock. Have you seen how ZMAPP is running into problems with the animal cell side. The antibodies wont grow right. cover
Wait tell hey help with the ZMAP pipeline ............. they are running ino problems with hamster overies. IT WONT RAMP !!!!!!!!!!!!!!!!!!! Hard to grow antibodies....................... Plants are in............... Robert is telling them to go pant and with their technologies. They can ramp............. I wish he could explain NOVICI. Even talk about CMB center for molecular biology ....... the solutions are there-their...... Shorts are in trouble soon.
. The animal cell process is not going good as growing the antibodies in plants. The antibodies do not grow as well as in plants. Quote from Loftus piece on one drug maker ramps '''' One challenge to overcome with that approach, though: One of the antibodies in the drug doesn’t reproduce as well in animals as in plants.''' cut and paste if you have a problem...... ROBERT IS RIGHT again.... At the Fraunhofer Center for Molecular Biotechnology in Delaware, racks of N. benthamiana plants can be programmed to produce a wide variety of vaccines. The next time an epidemic hits, PMP production could create 2.5 million units of vaccine in just one week. CMB is a IBIO partner...
US News came out with a story about MAPP trying to make ZMapp with animal cells from hamster ovaries. We knew they were going through Amgen, well they are having problems because the antibodies don't grow as well as in plants. MAPP is trying to ramp with other plant facilities..... DDDDaaaaa ! lets go people they need added technology as they contacted NOVICI .....This could be a deciding facture with BARDA . Barda will most likely use different manufacturers. How big of role could be a question???? BUT, having some roll is almost guaranteed at this point. The platform is in as far as I can see.
just investigation lies , fabrications and twisted stories from a little web site designed to mislead...Hmmmmmm
US NEWS –Loftus- Mapp is trying different approaches with ZMAPP. - Several Western and African patients have been given experimental treatments, including from Tekmira, Mapp Biopharmaceutical Inc. and Chimerix Inc., with the hope they might be effective. MAPP said it is expanding its tobacco growing facilities. Mapp is working with the Gates foundation and an outside company to grow antibodies in hamsters. The animal cell process is not going good as growing the antibodies in plants. The antibodies do not grow as well as in plants.
advantages over other systems
Ability to synthesize complex proteins at which other systems have failed
Simplicity, scalability and flexibility
Reduced capital investment
Lower operating costs
Rapid production times – gene sequence to factory-scale protein harvest
Eliminates the need of bioreactors
Low risk of contamination by animal pathogens GE, CALIBER ,NOVICI,IBIO ,Fraunhofer USA Center for Molecular Biotechnology , GATES, DOD, DARPA, Kanematsu Chemicals Corporation ,Oswaldo Cruz Foundation-brazil, China building 3 IBIO plants all with out contracts the basher would like you to think.......its about many successes and diseases. ...... , ITS disruptive- iBioLaunch platform has been proven
A lot smarter then GE, CALIBER ,NOVICI,IBIO ,Fraunhofer USA Center for Molecular Biotechnology , GATES, DOD, DARPA, Kanematsu Chemicals Corporation ,Oswaldo Cruz Foundation-brazil, China building 3 IBIO plants all with out contracts the basher would like you to think.......its about many successes and diseases. ...... , ITS disruptive- iBioLaunch platform has been proven to
IBIO has a platform used for many diseases to limit it to ONE disease is crazy. DONT be deceptive and illogical. That is twisting facts and counter productive to common sense. he iBioLaunch expression platform has been used to manufacture vaccine candidates that represent a broad range of viral, bacterial, and parasitic threats to human health. The technology has been used to successfully produce vaccine components that could not be manufactured using bacterial, yeast, or animal cell expression systems, demonstrating a breadth of application that is unmatched. Each of these vaccines is available to be licensed from iBio along with the iBioLaunch manufacturing platform, providing a turnkey entry into vaccine development and manufacturing. Influenza vaccines — As part of its collaboration with external agencies such as the Bill & Melinda Gates Foundation Global Health Initiative and the US Department of Defense Advanced Research Projects Agency, subunit vaccines for avian influenza (H5N1) and pandemic influenza (H1N1) have been created and advanced into human safety and immunogencity clinical studies. These vaccines consist of the viral hemagglutinin (HA) antigen, which is known to produce a protective immune response in humans. Yellow Fever- In partnership with Fiocruz/Bio-Manguinhos of Brazil , iBio and its research collaborator, the Fraunhofer USA Center for Molecular Biotechnology, have undertaken the development of this next-generation yellow fever vaccine. A license agreement for the iBioLaunch manufacturing platform applied to the yellow fever vaccine has been established with Fiocruz/Bio-Manguinhos and, by mutual agreement, may be expanded to include other product applications. Malaria — Malaria is one of the greatest threats to human health in the world. This vaccine candidate, which has shown great promise in laboratory studies of malaria transmission, was developed in a partnership with the Bill & Melinda Gates Foundation Gl
do the research on Kentucky please. They can only ramp twenty doses a month............ DEAD hoarse. They helped make it and are not a factor going foreword. Icon will get licensing money and the real production will come from the biggest plant Caliber. Kentucky is nothing but developmental. November the contracts from Barda. YOU are blind and don't follow the players. ITS a small sector designed by the Government, homeland, DOD and Darpa. The government contracts are there. The preparation for the out break is there the Barda money is there and every body but you knows whats going on. maybe you should read the 10K and platform for many different diseases again. English cant be your first language? ITS clear the government agencies protect against many diseases as the IBIO 10K. YES the platform and contracts apply. READ the NOVICI contract between IBIO and NOVICI. Do you think MAPP contacted them for a reason- NY Times news.